Cero Therapeutics Holdings, Inc. Files 8-K
Ticker: CEROW · Form: 8-K · Filed: Sep 18, 2024 · CIK: 1870404
Sentiment: neutral
Topics: corporate-filing, name-change, company-information
Related Tickers: CERO
TL;DR
Cero Therapeutics (CERO) filed an 8-K confirming its identity and past name change from Phoenix Biotech Acquisition Corp.
AI Summary
On September 18, 2024, Cero Therapeutics Holdings, Inc. filed an 8-K report. The filing indicates that the company's former name was Phoenix Biotech Acquisition Corp., with a name change effective June 30, 2021. The report details the company's incorporation in Delaware and its primary business in biological products.
Why It Matters
This filing provides official confirmation of Cero Therapeutics Holdings, Inc.'s corporate identity and history, including its previous name and incorporation details.
Risk Assessment
Risk Level: low — This filing is primarily administrative, confirming corporate details and not indicating any immediate financial or operational risks.
Key Numbers
- 001-40877 — Commission File Number (Identifies the company's filing with the SEC)
- 87-1088814 — IRS Employer Identification Number (Company's tax identification number)
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- Phoenix Biotech Acquisition Corp. (company) — Former company name
- September 18, 2024 (date) — Date of report
- June 30, 2021 (date) — Date of name change
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the primary business of Cero Therapeutics Holdings, Inc.?
Cero Therapeutics Holdings, Inc. is involved in Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
When did Cero Therapeutics Holdings, Inc. change its name?
The company's name change from Phoenix Biotech Acquisition Corp. was effective on June 30, 2021.
In which state was Cero Therapeutics Holdings, Inc. incorporated?
Cero Therapeutics Holdings, Inc. was incorporated in Delaware.
What is the SEC file number for Cero Therapeutics Holdings, Inc.?
The SEC file number for Cero Therapeutics Holdings, Inc. is 001-40877.
What is the business address of Cero Therapeutics Holdings, Inc.?
The business address is 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA 94080.
Filing Stats: 1,193 words · 5 min read · ~4 pages · Grade level 12.7 · Accepted 2024-09-18 16:02:35
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CERO NASDAQ Global Market
Filing Documents
- ea0215030-8k_cerothera.htm (8-K) — 34KB
- 0001213900-24-079867.txt ( ) — 250KB
- cero-20240918.xsd (EX-101.SCH) — 4KB
- cero-20240918_def.xml (EX-101.DEF) — 26KB
- cero-20240918_lab.xml (EX-101.LAB) — 36KB
- cero-20240918_pre.xml (EX-101.PRE) — 25KB
- ea0215030-8k_cerothera_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On September 10, 2024, CERo Therapeutics Holdings, Inc. (the "Company") announced that its special meeting of stockholders (the "Special Meeting") was postponed to 10:00 a.m. Eastern Time on September 19, 2024. On September 18, 2024, the Company announced that its special meeting of stockholders (the "Special Meeting") will be further postponed from its scheduled time of 10:00 a.m. Eastern Time on September 19, 2024 to 10:00 a.m. Eastern Time on September 26, 2024. The Special Meeting will continue to be held virtually at www.cstproxy.com/cero/2024. There will be no change in the record date for the Special Meeting, which was August 26, 2024. Stockholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not take any action. Stockholders as of the record date can vote, even if they have subsequently sold their shares. Any stockholders who wish to change their vote and need assistance should contact Advantage Proxy, Inc. at 1-877-870-8565, or ksmith@advantageproxy.com. Participants in the Solicitation The Company, and its respective directors and executive officers, and other members of their management and employees, under the rules of the Securities and Exchange Commission ("SEC"), may be deemed participants in the solicitation of proxies of the Company's stockholders in respect of the items of business at the Special Meeting. Information about the directors and executive officers of the Company is set forth in the Company's Definitive Proxy Statement on Schedule 14A relating to the Special Meeting of Stockholders, filed with the SEC on August 26, 2024 and in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 2, 2024 and in the Company's other filings with the SEC. Additional information regarding the identity of all potential participants in the solicitation of proxies to the Company's stockholders in connection w
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 18, 2024 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Brian G. Atwood Name: Brian G. Atwood Title: Chief Executive Officer 2